Bone Scan Index (BSI)

Bone Scan Index (BSI) was developed by a research group at the Memorial Sloan Kettering Cancer Center in New York as a method of expressing the tumour burden in bone as a percentage of the total skeletal mass and they showed that on-treatment change in BSI was strongly associated with overall survival for patients receiving chemotherapy. Their method of calculating BSI is manual, subjective, time-consuming and tedious, and this has limited the use of BSI outside the institution where it was developed.

Our contributions in this field have been innovative in that we have developed a fully automated method of bone scan analysis eliminating the need for operator manipulation. With our approach the BSI value will be the same in all hospitals performing this examination − an important feature for an imaging biomarker. We are currently working on analytical and clinical validation of BSI as part of an evidentiary process qualifying BSI as an imaging biomarker for prostate cancer in the context of clinical care and clinical trials.

The work has been performed in close collaboration with EXINI diagnostics AB and researchers at the Memorial Sloan Kettering Cancer Center in New York, Skåne University hospital in Malmö, Odense University Hospital in Malmö and Kanazawa University Hospital in Japan.

More info

A software for automated calculation of BSI is provided by EXINI diagnostics AB.